Photoangioplasty for human periphoseral atheroscleosis results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin)

Circulation

Volumn 102, Issue 19 SUPPL., 2000, Pages 2322-2324

  Rockson, S G ^a   Kramer, P ^a   Razavi, M ^a   Szuba, A ^a   Filardo, S ^a   Fitzgerald, P ^a   Cooke, J P ^a   Yousuf, S ^a   DeVault, A R ^a   Renschler, M F ^a   Adelman, D C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Catheters; Peripheral vascular disease

Indexed keywords

LUTETIUM TEXAPHYRIN; PHOTOSENSITIZING AGENT; SINGLET OXYGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PHASE 1 CLINICAL TRIAL; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR LOCALIZATION; ECHOGRAPHY; METHODOLOGY; PHOTOCHEMOTHERAPY;

HUMANS; PERIPHERAL VASCULAR DISEASES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; ULTRASONOGRAPHY;

EID: 0034619278     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.19.2322     Document Type: Article

References (8)

1. Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy
2. Photosensitization
3. How does photodynamic therapy work?
4. Lutetium texaphyrin (PCI-0123): A near-infrared, water-soluble photosensitizer
5. Phototherapy of cancer and atheromatous plaque with texaphyrins
6. Localization and efficacy analysis of the phototherapeutic lutetium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model
7. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease
8. Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer